Jeremy Grantham's Shocking Market Prediction 2023 S&P 500 Crash & Top Stocks to Watch!

요약 보기

결론: 그랜섬은 S&P500 급락 가능성을 경고하며, 보수적 방어 포트폴리오(헬스케어 중심)를 제시했다. 시장 하락 전망 그랜섬은 S&P500이 약 3,000포인트(현 수준 대비 약 30% 하락)까지 밀릴 수 있다고 봤다. 최악의 경우 2,000포인트(약 50% 하락)까지 갈 수 있다고 경고했다. 근거는 대형 기술주(이른바 'Magnificent 7')에 지수가 과도하게 의존하고 있고 밸류에이션이 높다는 점이다. 과거 적중 이력 그랜섬은 닷컴 버블 붕괴와 2008년 금융위기를 사전에 맞힌 것으로 언급됐다. 포트폴리오 동향(13F 기준) 2023년 3분기에 세 개 종목 지분을 직전 분기 대비 10% 이상 늘렸다. 유나이티드헬스(UNH) 2013~2023년 매출이 1,220억 달러에서 3,590억 달러로 증가해 연평균 약 11% 성장했다. 주가는 매출의 약 1.4배, 순이익의 약 24배 수준으로 거론됐다. 존슨앤드존슨(J&J) 2005년부터 장기 보유 중이며 2023~2027년 EPS 연 4.3% 성장이 예상된다고 언급됐다. 배당수익률은 3.2%, 배당성향은 47%다. 공정가치 182달러 대비 현재가 약 152달러로 저평가 가능성이 제시됐다. 머크(MRK) 포트폴리오의 약 1.96%를 차지한다. 최근 5년 주가는 약 43% 올랐고, 배당은 주당 48센트에서 73센트로 늘었다. 선행 PER은 12.1배, 향후 5년 EPS 연 14.4% 성장이 전망된다고 했다. 전략 요약 헬스케어와 저평가 성장주 중심, 분산 투자로 위험을 줄이는 접근을 강조했다. 출연자 이름 외 전망 대상 자산(S&P500 등)에 대한 1~3개월 단기 방향 예측은 명확하지 않으며, 장기적 하락 경고 중심이다.

다듬은 글

※ 자동 자막 원문(다듬기 전)

01. welcome to inves toy where Finance meets foresight today we're diving deep into the world with a focus on one of the most renowned figures in the field Jeremy Grantham imagine a world where the stock market takes a nose dive sending shock waves through your Investments this isn't just a hypothetical scenario it's a prediction from a man who has eerily been right before stick around as we unveil the details of this chilling forecast and explore strategies to safeguard your portfolio Jeremy Grantham the co-founder of GMO and a maestro in Market predictions recently made headlines on Bloomberg's Marin talks money podcast known for his sharp Acumen Grantham has rung the alarm Bells with a dire warning a potential crash in the SP 500 but how severe could this be according to Grand we might see the SP plummet to about 3,000 points marking a near 30% decline from its current standings and if the conditions worsen brace yourselves for what he describes as a worst case scenario a staggering fall to 2,000 points a jaw-dropping 50% decline now why should we pay attention to grantham's predictions the answer lies in his track record he's not just any Market analyst he's the one who accurately called the do bust and the 2008 financial crisis his forecasts aren't mere speculation they're based on years of experience and deep Market understanding grantham's current view paints a picture of an overvalued Market heavily ryant on a group he refers to as The Magnificent 7 in these are primarily Tech Giants driving much of the SP 500's value but what happens when these overvalued stocks start to correct that's the Crux of grantham's concern ER turning our Focus to grantham's investment strategy let's delve into his moves in the third quarter of 2023 as revealed by 13 F filings these filings provide a window into the minds of major investors showing us where they're placing their bets in Q3 of 2023 Grantham made significant moves by increasing his stakes in three key Stocks by over 10% compared to the second quarter this decision indicates a strategic shift highlighting his confidence in these Investments amidst a turbulent Market forecast if you're finding this insight into grantham's strategies enlightening remember to hit that subscribe button we bring you the latest and most profound investment insights right here on inves ay as we navigate these predictions and strategies it's crucial to understand the implications for your Investments what do these moves mean for the average investor stay tuned as we analyze each of these key stocks in detail unraveling the potential behind grantham's choices let's take a closer look at the specifics of grantham's Investments starting with United Health Group Incorporated or un this Healthcare giant has seen a significant uptick in grantham's attention with a notable increase in stakes in the latter half of 2023 but why UNH the answer lies in its performance and financials from 2013 to 2023 UNH has shown a remarkable trajectory its Revenue surged from $122 billion in 2013 to an impressive $359 billion in 2023 that's a compound annual growth rate cagr of over 11% it's not just about the numbers it's about consistent growth in both revenue and net income a sign of a company that knows how to grow and sustain itself in terms of valuation UNH is trading at one point four times its sales and 24 times its net income these figures are crucial for investors as they help gauge the Stock's relative value a low price to sales ratio might suggest undervaluation making it an attractive Buy on the other hand the price to earnings ratio offers insight into how much investors are willing to pay for each dollar of earnings a vital indicator of Market sentiment next on grantham's list is Johnson and Johnson or J&J a household name J&J has been a long-term holding for Grantham stretching back to 2005 this longevity speaks volumes about the company's stability and grantham's confidence in it but what makes J&J a robust pick in grantham's portfolio Financial strength is a key factor J&J boasts a high return on Capital employed a metric that measures how effectively a company generates profits from its capital additionally the company projects a stable earnings per share growth of 4.3% annually from 2023 to 2027 this steady growth is a green flag for any investor looking for sustainable returns J&J also offers a dividend yield of 3.2% with a 47% EPS payout ratio Dividends are a critical aspect for many investors especially those seeking regular income from their Investments a yield of 3.2% is substantial especially in a low interest rate environment the valuation of J&J also merits attention as of November 2019 2023 its fair value per share stands at $182 while the current price hovers around1 152 this Gap indicates potential undervaluation suggesting room for growth and making it an attractive proposition for investors looking for Value buys now let's turn our Spotlight to another key player in grantham's portfolio Merk and Co Inc commonly known as MRK this pharmaceutical giant occupies a significant 1.96% of grantham's portfolio reflecting a deep-seated confidence in its potential but what's driving this confidence let's break it down over the Last 5 Years MRK has seen an impressive 43% increase in its stock value translating to an average annual growth of 7.4% this steady Ascent is a testament to mrk's resilience and strategic business model especially in a sector as volatile as Pharmaceuticals it's not just about short-term gains it's the consistency of growth that makes MRK a standout a crucial Factor contributing to mrk's appeal is its dividend growth in The Last 5 Years mrk's dividend per share has climbed from 48 cents to 73 this 88.7% annual growth in dividends is a significant indicator for investors especially those prior prioritizing income alongside capital appreciation it shows mrk's commitment to returning value to its shareholders an essential quality in a long-term investment the company's performance in the third quarter of 2023 further cements its status MRK reported a robust 7% year-over-year sales growth boyed by a staggering $6.3 billion revenue from one of its key drugs this impressive figure highlights mrk's ability to generate substan revenue streams a critical factor in sustaining growth and shareholder value from a valuation perspective MRK is currently trading at a forward price to earnings ratio of 12.1 times this is significant because it provides a glimpse into what the market is willing to pay today for a share of mrk's future earnings moreover MRK is expected to see an annual EPS growth rate of 14.4% over the next 5 years this projection is a strong indicator of the company's potential for continued financial success and its ability to outperform the broader Market as we wrap up our Deep dive into Jeremy grantham's Market insights and investment strategies let's revisit and consolidate the key takeaways grantham's warnings about a significant Market downturn carry weight especially given his track record of accurately predicting major economic shifts These Warnings are not just alarm Bells but a call to action for Savvy investors the focal point of grantham's current investment strategy is particularly noteworthy he's placing a strong emphasis on the health sector and undervalued stocks with substantial growth potential this approach highlights a strategic shift towards Industries and companies that not only offer stability in turbulent times but also promise long-term growth the health sector as exemplified by grantham's investments in UNH J&J and MRK stands out as a resilient and potentially lucrative field grantham's Diversified portfolio is a master class in mitigating risks while capitalizing on growth opportunities in a market teeming with uncertainties this diversification is a critical strategy for balancing potential risks and rewards it's about not putting all your eggs in one basket but rather spreading them across baskets that have the strongest weave investing much like any strategic Endeavor requires foresight adaptability and an acute understanding of the market dynamics as we've seen through grantham's approach being well-informed and strategically Diversified can make a significant difference in navigating the stock market's es and flows if you found this analysis helpful and are keen on staying ahead in the investment game don't forget to like this video And subscribe to inves Ay for more insightful content our journey doesn't end here it's just the beginning with each video we aim to empower you with knowledge and insight to make informed investment decisions thank you for watching inves ay where we bring the world of Finance to your doorstep keep an eye on those markets stay informed and most importantly stay invested until next time keep building your financial future with inves ay